MiRNA | Tissue | Grade | n | Mean (SD) | Contrasts | p* |
---|---|---|---|---|---|---|
miR-17-5p | Benign | – | 36 | 6.67 (0.68) |  |  |
Cancer | All | 102 | 6.32 (0.66) | Cancer vs benign | 0.014 | |
Cancer | 1 | 32 | 6.10 (0.45) | Grade 1 vs 2 and 3 | 0.0040 | |
Cancer | 2 | 41 | 6.16 (0.48) | Grade 1 and 2 vs 3 | 2.45E−5 | |
Cancer | 3 | 27 | 6.82 (0.85) | Grade 1 vs 3 | 6.84E−5 | |
miR-20a-5p | Benign | – | 36 | 7.34 (0.74) |  |  |
Cancer | All | 102 | 6.69 (0.60) | Cancer vs benign | 1.23E−6 | |
Cancer | 1 | 32 | 6.54 (0.38) | Grade 1 vs 2 and 3 | 0.014 | |
Cancer | 2 | 41 | 6.52 (0.39) | Grade 1 and 2 vs 3 | 2.45E−5 | |
Cancer | 3 | 27 | 7.14 (0.82) | Grade 1 vs 3 | 8.50E−5 | |
miR-92a-3p | Benign | – | 36 | 7.79 (0.62) |  |  |
Cancer | All | 102 | 7.23 (0.52) | Cancer vs benign | 1.23E−6 | |
Cancer | 1 | 32 | 7.19 (0.47) | Grade 1 vs 2 and 3 | 0.27 | |
Cancer | 2 | 41 | 7.06 (0.42) | Grade 1 and 2 vs 3 | 0.00037 | |
Cancer | 3 | 27 | 7.55 (0.59) | Grade 1 vs 3 | 0.0068 | |
miR-106b-5p | Benign | – | 36 | 6.68 (0.59) |  |  |
Cancer | All | 102 | 6.56 (0.51) | Cancer vs benign | 0.24 | |
Cancer | 1 | 32 | 6.36 (0.38) | Grade 1 vs 2 and 3 | 0.0019 | |
Cancer | 2 | 41 | 6.49 (0.44) | Grade 1 and 2 vs 3 | 6.84E−5 | |
Cancer | 3 | 27 | 6.91 (0.61) | Grade 1 vs 3 | 6.84E−5 | |
miR-93-5p | Benign | – | 36 | 6.81 (0.41) |  |  |
Cancer | All | 102 | 7.00 (0.56) | Cancer vs benign | 0.095 | |
Cancer | 1 | 32 | 6.80 (0.39) | Grade 1 vs 2 and 3 | 0.0032 | |
Cancer | 2 | 41 | 6.92 (0.47) | Grade 1 and 2 vs 3 | 6.84E−5 | |
Cancer | 3 | 27 | 7.39 (0.69) | Grade 1 vs 3 | 8.50E−5 | |
miR-25-3p | Benign | – | 36 | 6.63 (0.33) |  |  |
Cancer | All | 102 | 6.54 (0.33) | Cancer vs benign | 0.19 | |
Cancer | 1 | 32 | 6.44 (0.23) | Grade 1 vs 2 and 3 | 0.013 | |
Cancer | 2 | 41 | 6.48 (0.28) | Grade 1 and 2 vs 3 | 0.00016 | |
Cancer | 3 | 27 | 6.75 (0.41) | Grade 1 vs 3 | 0.00043 |